Given that IL-9 contributes to inflammation in the early phase of vaginal candidiasis, we asked whether a timely administration of an IL-9 neutralizing antibody could ameliorate vaginal pathogenesis. The gene discussed is IL9; the disease is vulvovaginal candidiasis.